InSite Vision Announces Positive Phase 3 Results for BromSite™ (ISV-303) for the Reduction of Inflam
ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB:INSV) today announced top-line results from its recently completed Phase 3 clinical trial of BromSite ™ (ISV-303) for the reduction ...
InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite™ for the Reduc
ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) today announced that the last patient has been enrolled in the confirmatory Phase 3 clinical trial of BromSite ™ (ISV-303) ...
InSite Vision (INSV.OB) just announced top-line results from its first Phase III trial of BromSite which is indicated for the reduction of inflammation and pain after cataract surgery. BromSite is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback